# Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

> **NCT03872401** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 12301 (actual)

## Conditions studied

- Coronary Heart Disease (CHD)

## Interventions

- **DRUG:** Evolocumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03872401
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-11
- **Primary completion:** 2025-07-25
- **Final completion:** 2025-07-25
- **Target enrollment:** 12301 (ACTUAL)
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03872401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03872401, "Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03872401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*